I already had COVID-19, but want to know if I have antibodies.

For your situation we recommend these options for testing:

SURVEILLANCE
COVID-19 Immune Response Panel
Learn more

Serum test that measures both nucleocapsid (N-protein) and S-RBD antibodies

The COVID-19 Immune Response Panel measures both nucleocapsid (N-protein) and S-RBD antibodies. N-protein antibodies do not rise in response to COVID-19 S-RBD vaccinations. The combined serum IgM/IgG tests measure the body’s response to COVID-19 nucleocapsid (N) and spike protein receptor-binding domain (S-RBD) exposure. The N and S-RBD antibodies’ combination assay has a > 99% positive and negative predictive value 15 days after COVID-19 exposure. This test does not differentiate between IgM and IgG; studies indicate that joint testing is as or more reliable than individual IgM and IgG testing in confirming COVID-19 exposure.

SURVEILLANCE
SARS-CoV-2 Quantitative IgG+IgM Antibody Panel
Learn more

COVID-19 antibody testing utilizes a serum sample to identify exposure to the SARS-CoV-2 virus, regardless of symptom presentation. The COVID-19 IgG + IgM Antibody Panel evaluates IgG and IgM reactivity separately, providing individual results for each. This may be useful for determining the current stage of infection.

This test is performed on a high-precision chemiluminescent immunoassay that has received FDA authorization under emergency use authorization (EUA).

In a human study of COVID-19 patients, the COVID-19 IgG + IgM Antibody Panel was found to meet the following specifications for sensitivity and clinical specificity:

IgG:

  • 100% Sensitivity
  • 97.4% Specificity
  • @ >15 days post-infection

IgM:

  • 94.4% Sensitivity
  • 98.3% Specificity
  • @ >15 days post-infection
}